Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2219 (LINC02219) is a human long intergenic non-protein coding RNA gene that does not code for a protein[1]. It belongs to the class of lincRNAs, which are defined as autonomously transcribed non-coding RNAs longer than 200 nucleotides that do not overlap with protein-coding genes[3][5]. lincRNAs can act to regulate gene expression (either locally or at a distance), participate in chromatin remodeling, scaffold protein complexes, and affect RNA stability or translation through various mechanisms[3][5]. While some lincRNAs have been associated with specific cellular and disease processes—including cancer—there are currently no experimentally validated functional roles, disease associations, or drug interactions for LINC02219 specifically as of available sources[1]. Thus, it is not considered a therapeutic target or druggable entity at present.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2219 (LINC02219).